BioSpace News Archive

Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-executive board member.

UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health - Europe (LINK).

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies.

Recro Pharma, Inc. announced the expansion of its team through the addition of new employees primarily in the areas of analytical development, business development, sales and marketing to support our continued growth and customer diversification efforts.

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to announce that it has received notification of intention to grant the patent “Compositions and Methods for Treatment and Prevention of Hyperuricemia Related Health Consequences” by the European Patent Office for this PCT international application.

Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, May 6, 2021 , at 8:00 a.m. CDT to review third quarter 2021 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: May 6, 2021

Financing Co-led by HBM Healthcare Investments and Samsara BioCapital Food and Drug Administration Accepts Investigational New Drug Application for MLS-101 and Advances to Phase 2 Proof-of-Concept Clinical Trial

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar , M.D., as Chief Medical Officer.

Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides

NeuPath Health Inc. (TSXV:NPTH) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, today announced Grant Connelly, CEO, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference.